Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 426 to 450 of 1141 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
716 decreased hypoxia (MP:0005039) hypoxia-inducible factor 1-alpha (PR:000008555) 1394: Induction, persistent proliferation/sustained proliferation
715 increased macrophage activation involved in immune response (GO:0002281) macrophage (CL:0000235) 1394: Induction, persistent proliferation/sustained proliferation
714 increased cellular response to oxidative stress (GO:0034599) 1394: Induction, persistent proliferation/sustained proliferation
713 decreased abnormal circulating hormone level (MP:0005418) None
712 decreased abnormal circulating hormone level (MP:0005418) 3,3',5-triiodo-L-thyronine (CHEBI:18258) None
711 decreased abnormal circulating hormone level (MP:0005418) 3,3',5'-triiodothyronine (CHEBI:28774) None
710 decreased abnormal circulating thyroxine level (MP:0005475) thyroxine (CHEBI:30660) 281: Thyroxine (T4) in serum, Decreased
709 increased endocytosis (GO:0006897) lysosomal membrane (GO:0005765) 1539: Endocytotic lysosomal uptake
708 abnormal chemical synaptic transmission (GO:0007268) synapse (GO:0045202) 758: Hippocampal Physiology, Altered
707 morphological change brain development (GO:0007420) hippocampal formation (UBERON:0002421) 757: Hippocampal anatomy, Altered
706 decreased regulation of hormone levels (GO:0010817) thyroxine (CHEBI:30660) 280: Thyroxine (T4) in neuronal tissue, Decreased
705 decreased fatty acid beta-oxidation (GO:0006635) 1528: Fatty Acid Beta Oxidation, Decreased
704 decreased testicular atrophy (MP:0003205) Testis (FMA:7210) None
703 decreased spermatocyte (CL:0000017) 1515: Spermatocyte depletion
702 increased increased apoptosis (MP:0006042) apoptosis fated cell (CL:0000445) None
701 disrupted regulation of cell cycle (GO:0051726) cell cycle-related cyclin (PR:000029191) 1505: Cell cycle, disrupted
700 increased positive regulation of gene expression (GO:0010628) cyclin-dependent kinase inhibitor (PR:000000014) 1504: p21 (CDKN1A) expression, increase
699 increased regulation of protein modification process (GO:0031399) histone (CHEBI:15358) 1503: Histone acetylation, increase
698 decreased enzyme inhibitor activity (GO:0004857) histone deacetylase 1 (PR:000008478) 1502: Histone deacetylase inhibition
697 decreased abnormal protein level (MP:0008469) vascular endothelial growth factor A (PR:000017284) 948: reduced production, VEGF
696 decreased vascular endothelial growth factor A (PR:000017284) None
695 increased acute inflammatory response (GO:0002526) 1493: Increased Pro-inflammatory mediators
694 increased cell activation involved in immune response (GO:0002263) 1492: Tissue resident cell activation
693 increased cell activation involved in immune response (GO:0002263) tissue-resident macrophage (CL:0000864) None
692 increased cell activation involved in immune response (GO:0002263) leukocyte (CL:0000738) 1494: Leukocyte recruitment/activation